[{"id":"a7682c56-3628-4450-82e0-083a09293128","acronym":"PhAST","url":"https://clinicaltrials.gov/study/NCT05495295","created_at":"2022-08-10T12:55:28.015Z","updated_at":"2024-07-02T16:35:05.753Z","phase":"Phase 1","brief_title":"First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours","source_id_and_acronym":"NCT05495295 - PhAST","lead_sponsor":"Phost'In Therapeutics","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 overexpression • HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PhOx430"],"overall_status":"Recruiting","enrollment":" Enrollment 149","initiation":"Initiation: 07/18/2022","start_date":" 07/18/2022","primary_txt":" Primary completion: 07/08/2024","primary_completion_date":" 07/08/2024","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2024-05-06"}]